Skip to content 
If you’ve been researching the newest medications for weight loss, you’ve probably heard about retatrutide.
Early and late-stage clinical trial results have generated significant interest, with some patients already asking whether retatrutide is “better” than semaglutide—and when they will be able to get it.
There is one important distinction to understand first:
Semaglutide is available today in FDA-approved medications. Retatrutide is still an investigational medication and is not currently FDA-approved or commercially available.
At The Best Injector in Delray Beach, Florida, we provide medically supervised weight management for appropriate patients using currently available treatment options. We do not currently offer retatrutide.
However, because retatrutide may represent an important future development in obesity medicine, patients deserve accurate information about what it is, how it differs from existing medications, what the clinical trials are showing, and when it could potentially become available.
We serve patients throughout Delray Beach, Boca Raton, Boynton Beach, Highland Beach, Gulf Stream, and surrounding Palm Beach County communities.
Semaglutide is a GLP-1 receptor agonist.
GLP-1, or glucagon-like peptide-1, is involved in appetite regulation, satiety, glucose-dependent insulin secretion, and other metabolic processes.
Semaglutide mimics the activity of GLP-1 and can help appropriate patients:
Semaglutide is the active ingredient in FDA-approved medications including Wegovy for chronic weight management in eligible patients and Ozempic for specific indications involving type 2 diabetes.
It has been extensively studied and has years of clinical use behind it.
Retatrutide is an investigational once-weekly injectable medication being developed by Eli Lilly.
What makes retatrutide particularly interesting is that it activates three different hormone receptors:
GLP-1 + GIP + glucagon
This is why retatrutide is commonly described as a triple agonist or triple hormone receptor agonist.
That makes it mechanistically different from both semaglutide and tirzepatide.
Targets:
GLP-1
Targets:
GLP-1 + GIP
Targets:
GLP-1 + GIP + glucagon
The addition of glucagon receptor activity is one of the features researchers are investigating as a potential contributor to retatrutide’s effects on energy balance and body weight.
The weight-loss results observed in clinical trials have been substantial.
In the earlier Phase 2 obesity trial, participants receiving the highest studied retatrutide dose experienced an average body-weight reduction of approximately 24% at 48 weeks.
More recently, Phase 3 results have continued to generate attention.
In the TRIUMPH-4 Phase 3 trial involving adults with obesity or overweight and knee osteoarthritis, participants receiving the 12 mg dose lost an average of approximately 29% of their starting body weight at 68 weeks under the efficacy estimand.
Other Phase 3 trials have also reported substantial average weight reductions in populations with obesity and associated medical conditions.
These are impressive clinical-trial findings.
But they require context.
Trial averages are not individual guarantees, different trials cannot always be directly compared, and retatrutide’s complete long-term safety and efficacy profile is still being evaluated.
The biggest difference is their mechanism.
Semaglutide activates one primary metabolic hormone receptor pathway: GLP-1.
Retatrutide activates three: GLP-1, GIP, and glucagon.
Both affect appetite and metabolic signaling, but retatrutide’s additional receptor activity may produce different effects on energy balance and metabolism.
There is another major difference:
Semaglutide has FDA-approved formulations and is available now. Retatrutide does not and is not.
That distinction matters more than any theoretical comparison between the two medications today.
Current trial results suggest that retatrutide has the potential to produce very substantial weight reduction.
However, it is important not to compare percentages from separate clinical trials as though the medications were tested head-to-head under identical circumstances.
Study populations, treatment duration, doses, inclusion criteria, statistical methods, and other variables differ.
So while retatrutide’s results are extremely promising, saying that it has definitively been proven “better than semaglutide” oversimplifies the evidence.
More importantly, the medication that produces the largest average weight-loss percentage is not automatically the best treatment for every individual patient.
Tirzepatide provides another useful comparison.
Tirzepatide activates GIP and GLP-1 receptors, placing it mechanistically between semaglutide and retatrutide.
So the three can broadly be understood as:
Semaglutide → GLP-1
Tirzepatide → GIP + GLP-1
Retatrutide → GIP + GLP-1 + glucagon
Tirzepatide is already available in FDA-approved medications, including Zepbound for eligible patients requiring chronic weight management.
Retatrutide remains investigational.
For patients seeking medical weight loss now, there is no reason to assume they need to wait for a future medication before addressing their weight.
No.
As of August 2026, retatrutide is not FDA-approved for weight loss or any other indication.
It remains an investigational medication under clinical development by Eli Lilly.
This is particularly important because products marketed online as “retatrutide” have become increasingly common.
The existence of a vial for sale on the internet does not mean there is an FDA-approved retatrutide product available.
There isn’t.
This deserves a very clear answer:
Retatrutide cannot currently be legally used in compounding under federal law.
The FDA has specifically addressed this issue.
Retatrutide is not a component of an FDA-approved drug and has not been found safe and effective for any condition.
Patients should therefore be extremely cautious about clinics, websites, peptide companies, or other sellers claiming to provide compounded retatrutide.
Products labeled:
“For research use only”
or
“Not for human consumption”
should not be interpreted as legitimate medications for personal use.
The FDA has specifically warned about unapproved products containing—or claiming to contain—retatrutide being sold directly to consumers.
With an unregulated product, there may be no reliable way for a patient to know whether the vial contains the claimed compound, the correct concentration, contaminants, impurities, or something else entirely.
The Best Injector does not currently offer retatrutide.
Retatrutide is being evaluated in an extensive Phase 3 clinical development program known as TRIUMPH.
Research has included patients with obesity or overweight and populations with conditions such as:
Recent Phase 3 results have continued to show substantial reductions in body weight.
For example, in TRIUMPH-2, adults with obesity or overweight and type 2 diabetes receiving the highest studied dose experienced average weight loss of approximately 21% at 80 weeks.
In TRIUMPH-3, adults with severe obesity and established cardiovascular disease experienced average weight loss of approximately 23% at 80 weeks at the highest studied dose.
And in TRIUMPH-4, participants with obesity or overweight and knee osteoarthritis receiving 12 mg experienced average weight reduction approaching 29% at 68 weeks under the efficacy estimand.
These results help explain why retatrutide is generating significant interest.
Because retatrutide remains investigational, its safety profile continues to be evaluated.
Gastrointestinal side effects have been common in clinical trials, similar to other medications affecting GLP-1 pathways.
Reported effects have included symptoms such as:
Earlier research also identified dose-dependent increases in heart rate, which is one reason continued cardiovascular and long-term safety evaluation is important.
A medication producing impressive weight loss still needs an acceptable safety profile.
That is exactly what the clinical trial and regulatory processes are designed to establish.
There is no guaranteed FDA approval date.
However, the development timeline has become clearer.
In July 2026, Eli Lilly announced positive results from additional pivotal Phase 3 trials and stated that it plans to submit retatrutide to the FDA in the first quarter of 2027.
Submitting an application does not mean the medication is approved.
The FDA must review the complete clinical data and determine whether the medication’s benefits outweigh its risks for the proposed indication.
Therefore, patients should be cautious about websites claiming that retatrutide has a definite release date.
It does not.
If approved, commercial availability would occur only after completion of the regulatory process.
For most patients who currently meet criteria for medical treatment of overweight or obesity, waiting for a medication that has not yet been approved may not make sense.
There are already evidence-based treatment options available.
Depending on individual medical history and eligibility, current treatment may include medications such as semaglutide or tirzepatide, alongside appropriate nutrition, activity, resistance training, and medical monitoring.
If retatrutide eventually receives FDA approval, it may become another option that can be considered at that time.
Starting an appropriate treatment today doesn’t prevent someone from reevaluating their options in the future.
The excitement surrounding newer medications has created an unintended problem:
Weight-loss medications are increasingly discussed as though the goal is simply to identify which drug produces the biggest percentage on a clinical-trial graph.
That’s not how individualized medical care should work.
More weight loss is not automatically better.
For an individual patient, we need to consider:
Someone who needs to lose 20 pounds does not necessarily benefit from the medication capable of producing the greatest average weight reduction in a clinical trial.
The appropriate treatment is the one that makes sense for the patient.
Regardless of which medication is being used, significant weight loss can include loss of lean tissue.
This becomes particularly important as weight loss becomes larger.
At The Best Injector, we believe successful medical weight management should look beyond total scale weight.
Adequate nutrition, sufficient protein, resistance training, and monitoring body composition can help keep the focus on losing excess fat while preserving valuable skeletal muscle.
Our InBody 570 body composition analysis can provide additional information about changes in body fat, skeletal muscle, visceral fat, and other body-composition measurements during a weight-management program.
The goal shouldn’t simply be:
“How much weight did I lose?”
A better question is:
“What did I lose?”
At The Best Injector in Delray Beach, Florida, we provide individualized medical weight management for eligible patients.
Treatment is led by Lianne Hahn, PA-C, a board-certified Physician Assistant with more than a decade of experience in medicine, aesthetics, and patient care.
Depending on medical history, eligibility, and individual goals, currently available treatment options may include semaglutide, tirzepatide, body composition assessment, and individualized medical weight-management strategies.
We do not currently offer retatrutide because it remains investigational and is not FDA-approved.
If its regulatory status changes in the future, new evidence and FDA-approved indications can be evaluated at that time.
Patients throughout Boca Raton are increasingly searching for information about semaglutide, tirzepatide, and emerging medications such as retatrutide.
The Best Injector is located nearby in Delray Beach, Florida, and provides individualized medical weight management for patients throughout Boca Raton and southern Palm Beach County.
If you’re searching for semaglutide near Boca Raton or want to understand how current GLP-1 treatment compares with emerging medications such as retatrutide, a medical consultation can help determine which currently available option may be appropriate.
We also serve patients from Boynton Beach, Highland Beach, Gulf Stream, and surrounding Palm Beach County communities.
No FDA-approved retatrutide is currently available in Delray Beach—or anywhere else in the United States. Retatrutide remains an investigational medication and is currently available legitimately only through appropriate clinical research.
No. The Best Injector does not currently offer retatrutide. It is not FDA-approved and cannot currently be legally used in compounding under federal law.
We continue to follow emerging obesity-treatment research and can discuss the current evidence and available medical weight-management options during consultation.
Retatrutide has produced substantial weight reduction in clinical trials, but comparing percentages across separate studies does not establish which medication is “better” for an individual patient. Semaglutide has FDA-approved formulations and is currently available, while retatrutide remains investigational.
Retatrutide targets GLP-1, GIP, and glucagon receptors, while semaglutide—the active ingredient in Ozempic—targets GLP-1 receptors. Retatrutide has produced substantial weight loss in obesity trials, but it remains investigational and is not an approved alternative to Ozempic.
No. Tirzepatide targets GIP and GLP-1 receptors. Retatrutide targets GIP, GLP-1, and glucagon receptors.
Products claiming to contain retatrutide are being sold online, but retatrutide is not FDA-approved or commercially available. FDA has warned consumers about unapproved products sold as retatrutide, including products marketed as being for “research use.”
No. FDA currently states that retatrutide cannot be used in compounding under federal law.
There is no confirmed release date. Eli Lilly has announced plans to submit retatrutide to the FDA in the first quarter of 2027. Commercial availability would depend on subsequent regulatory review and approval.
There are FDA-approved medications currently available for chronic weight management in eligible patients, including medications containing semaglutide and tirzepatide. Which treatment is appropriate depends on individual medical history, BMI, weight-related conditions, contraindications, and goals.
The Best Injector is located in Delray Beach, Florida, convenient to Boca Raton and surrounding Palm Beach County communities. We provide individualized medical weight-management consultations and can determine whether semaglutide, tirzepatide, or another currently available strategy is appropriate.
Retatrutide may ultimately become an important addition to obesity medicine.
The Phase 3 results reported to date are compelling, and the planned FDA submission represents an important next step.
But promising isn’t the same thing as approved.
Until the FDA completes its regulatory review, products being sold as retatrutide should not be treated as legitimate substitutes for an approved medication.
For patients who want to address their weight today, there are already established treatment options available.
At The Best Injector in Delray Beach, we provide individualized medical weight management and body-composition monitoring for appropriate patients throughout Delray Beach, Boca Raton, Boynton Beach, Highland Beach, Gulf Stream, and surrounding Palm Beach County.
Schedule a medical weight loss consultation to discuss currently available options and determine which approach may be appropriate for you.
This article is for educational purposes only and does not constitute individualized medical advice. Retatrutide is investigational and is not currently FDA-approved. Individual treatment decisions require appropriate medical evaluation.
Lianne Hahn, PA-C is an NCCPA board-certified Physician Assistant and founder of The Best Injector, a boutique medical aesthetics and wellness practice in Delray Beach, Florida. With more than 13 years of clinical experience across aesthetics, dermatology, primary care, medical weight management, and wellness, Lianne combines advanced clinical knowledge with an individualized approach to patient care.
At The Best Injector, Lianne personally evaluates and treats patients from Delray Beach, Boca Raton, Palm Beach County, and throughout South Florida. Her practice offers advanced injectable aesthetics, facial balancing, medical weight management, GLP-1 treatment when clinically appropriate, InBody 570 body composition analysis, microneedling, regenerative treatments, and personalized wellness services.
Lianne’s approach emphasizes appropriate patient selection, individualized treatment planning, natural-looking aesthetic outcomes, and evidence-informed medical care rather than one-size-fits-all treatment protocols.
Author & Medical Reviewer: Lianne Hahn, PA-C
Credentials: NCCPA Board-Certified Physician Assistant
Clinical Experience: 13+ Years
Practice: The Best Injector | Delray Beach, Florida
Serving: Delray Beach, Boca Raton & South Florida
If you’re considering aesthetic treatment, medical weight management, body composition analysis, or wellness services in Delray Beach or Boca Raton, schedule a personalized consultation with Lianne Hahn, PA-C at The Best Injector to determine which treatment options may be appropriate for your individual goals.
This article is intended for educational purposes only and does not replace individualized medical evaluation, diagnosis, or treatment. Treatment eligibility, recommendations, risks, and expected outcomes vary by patient.
